bioimagesUnknownPatrick W. OakesThe Journal of Cell Biologyhttps://www.ebi.ac.uk/biostudies/studies/S-JCBD-201107042JCB

Shown is a wild-type 3T3 cell treated with formin inhibitor, plated on a fibronectin-coated glass coverslip, and fixed and stained for fibronectin 24 hours after plating.

Shown is a wild-type 3T3 cell treated with alpha-actinin1 shRNA, plated on a fibronectin-coated glass coverslip, and fixed and stained for paxillin 24 hours after plating.

A series of images at 30 sec intervals is shown of GFP-actin expressed in a protruding wild-type U2OS cell treated with alpha-actinin1 shRNA.

Shown is a wild-type 3T3 cell treated with alpha-actinin1 shRNA, plated on a fibronectin-coated glass coverslip, and fixed and stained for fibronectin 24 hours after plating.

Shown is a wild-type 3T3 cell plated on a fibronectin-coated glass coverslip and fixed and stained for actin 24 hours after plating.

An image of F-actin visualized by fluorescent phalloidin (red) and paxillin immunofluorescence (green) is shown for a fixed wild-type U2OS cell with reduced expression of α-actinin 1 by shRNA.

An immunofluorescence image of myosin light chain phosphorylated at Serine 19 (pMLC) is shown for a fixed wild-type U2OS cell.

An immunofluorescence image of myosin light chain phosphorylated at Serine 19 (pMLC) is shown for a fixed wild-type U2OS cell treated with formin inhibitor.

Shown is a wild-type 3T3 cell plated on a fibronectin-coated glass coverslip and fixed and stained for fibronectin 24 hours after plating.

Shown is a wild-type 3T3 cell treated with formin inhibitor, plated on a fibronectin-coated glass coverslip, and fixed and stained for paxillin 24 hours after plating.

An image of F-actin visualized by fluorescent phalloidin (red) and paxillin immunofluorescence (green) is shown for a fixed wild-type U2OS cell with reduced expression of Dia1 via siRNA.

An image of F-actin visualized by fluorescent phalloidin (red) and paxillin immunofluorescence (green) is shown for a fixed wild-type U2OS cell.

Shown is a wild-type 3T3 cell treated with alpha-actinin1 shRNA, plated on a fibronectin-coated glass coverslip, and fixed and stained for actin 24 hours after plating.

An image of F-actin visualized by fluorescent phalloidin (red) and paxillin immunofluorescence (green) is shown for a fixed wild-type U2OS cell treated with 15 μM of the formin inhibitor SMIFH2.

Shown is a wild-type 3T3 cell plated on a fibronectin-coated glass coverslip and fixed and stained for paxillin 24 hours after plating.

An immunofluorescence image of fluorescent phalloidin staining of F-actin is shown for a fixed wild-type U2OS cell treated with formin inhibitor.

Shown is a wild-type 3T3 cell treated with formin inhibitor, plated on a fibronectin-coated glass coverslip, and fixed and stained for actin 24 hours after plating.

An immunofluorescence image of fluorescent phalloidin staining of F-actin is shown for a fixed wild-type U2OS cell.

An immunofluorescence image of fluorescent phalloidin staining of F-actin is shown for a fixed wild-type U2OS cell treated with alpha-actinin1 shRNA.

An immunofluorescence image of myosin light chain phosphorylated at Serine 19 (pMLC) is shown for a fixed wild-type U2OS cell treated with alpha-actinin1 shRNA.

bioimagesImage 132985 (Figure 6 - B)Image 132968 (Figure 1 - A)Image 132980 (Figure 6 - B)Image 132986 (Figure 6 - B)Image 132972 (Figure 2 - A)Image 132984 (Figure 6 - B)Image 132981 (Figure 6 - B)Image 132967 (Figure 1 - A)Image 132973 (Figure 2 - A)Image 132975 (Figure 2 - A)Image 132979 (Figure 6 - B)Image 132983 (Figure 6 - B)Figure 1 - AImage 132982 (Figure 6 - B)Image 132974 (Figure 2 - A)Image 132976 (Figure 2 - A)Figure 6Image 132978 (Figure 6 - B)Image 132969 (Figure 1 - A)Image 132970 (Figure 1 - A)Image 132977 (Figure 2 - D)Figure 6 - BFigure 1Image 132971 (Figure 2 - A)Figure 2 - DFigure 2 - AFigure 2Yvonne BeckhamPatrick W. OakesJonathan StrickerMargaret L. GardelfalseTension is required but not sufficient for focal adhesion maturation without a stress fiber template2012-01-30T11:22:15Z2018-11-29T11:22:15Z2018-11-29T11:22:15ZS-JCBD-20110704210.1083/jcb.201107042